STRS Ohio’s AN2 Therapeutics ANTX Stock Holding History

STRS Ohio’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,300	Closed	-$22K	–	1940
2023 Q1	$22K	Hold	2,300	–	–	﹤0.01%	1861
2022 Q4	$21K	Buy	+2,300	New	+$30.8K	﹤0.01%	1880

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

STRS Ohio's ANTX Position: Q2 2023 in Review

STRS Ohio sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 2,300 shares — an estimated $22K sold.

STRS Ohio first reported a position in ANTX in Q4 2022 and held it in 2 quarters. The position peaked at $22K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

STRS Ohio reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
STRS Ohio sold 2,300 AN2 Therapeutics shares in Q2 2023, an estimated $22K.
STRS Ohio first reported a position in AN2 Therapeutics in Q4 2022 and held it in 2 quarters.
STRS Ohio's AN2 Therapeutics position peaked at $22K in Q1 2023.
31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on STRS Ohio's 13F filing for Q2 2023, filed 31 Jul 2023.